How to Buy Beta Drugs Ltd Shares?
You can easily buy the stocks/shares of Beta Drugs Ltd (BETA) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Beta Drugs Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of BETA as on 15th May 2025 is ₹1856.24What is the return on Beta Drugs Ltd share?
The past returns of Beta Drugs Ltd (BETA) share are- Past 1 week: N/A
- Past 1 month: N/A
- Past 3 months: -3.41
- Past 6 months: -7.48
- Past 1 year: 53.38
- Past 3 years: 206.54
- Past 5 years: 2890.32
What is the Dividend yield % on Beta Drugs Ltd share?
The current dividend yield of Beta Drugs Ltd (BETA) is N/AWhat is the Market Cap of Beta Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd (BETA) is ₹1796.78Cr as of 15th May 2025What is the 52 Week High and Low of Beta Drugs Ltd?
The 52-week high and low of Beta Drugs Ltd (BETA) is ₹2215.24 and ₹1121.90.What is the PE and PB ratio of Beta Drugs Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Beta Drugs Ltd are 42.36 and 11.44 respectively.Which sector does Beta Drugs Ltd belong to?
Beta Drugs Ltd (BETA) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Beta Drugs Ltd?
The peers or stocks similar to Beta Drugs Ltd are: and many others.Can't decide whether or not to buy Beta Drugs Ltd?
Worry no more! Login to Tickertape and check out Beta Drugs Ltd (BETA) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Beta Drugs Ltd?
The 52-week high and low of Beta Drugs Ltd (BETA) is ₹2215.24 and ₹1121.90.1. Test Stocks FAQ for Beta Drugs Ltd Shares?
You can easily buy the stocks/shares of Beta Drugs Ltd (BETA) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Beta Drugs Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of BETA as on 15th May 2025 is ₹1856.24
Beta Drugs Ltd
BETA Share Price
1,856.240.12% (+2.24)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BETA Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BETA Performance & Key Metrics
BETA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 11.44 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.91 | 6.52 | 0.79% |
BETA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BETA Company Profile
Beta Drugs Limited is a pharmaceutical formulation manufacturing company. It is engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Company also engaged manufacturing oncology products
SUNPHARMA
PE Ratio
36.65
36.65
1Y Return
10.92%
10.92%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.13
23.13
1Y Return
0.69%
0.69%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.74
19.74
1Y Return
10.36%
10.36%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
57.15
57.15
1Y Return
14.00%
14.00%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.67
21.67
1Y Return
9.05%
9.05%
Buy Reco %
46.43
46.43
BETA Sentiment Analysis
BETA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
BETA Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
BETA Stock Growth Drivers
BETA Stock Growth Drivers
4Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
BETA Stock Challenges
BETA Stock Challenges
4Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
BETA Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
BETA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BETA
BETA
Income
Balance Sheet
Cash Flow
Annual Normal View
BETA Income Statement
BETA Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 50.81 | 66.30 | 91.22 | 116.62 | 184.60 | 227.86 | 297.07 | 368.79 | — | |||||||||
Raw Materials | 28.15 | 37.26 | 45.21 | 60.55 | 96.21 | 110.40 | 167.65 | 292.32 | — | |||||||||
| Power & Fuel Cost | 0.89 | 1.21 | 1.95 | 2.75 | 3.43 | 4.79 | 6.35 | |||||||||||
| Employee Cost | 1.26 | 3.80 | 6.95 | 8.32 | 12.10 | 17.08 | 20.14 | |||||||||||
| Selling & Administrative Expenses | 4.85 | 7.82 | 10.27 | 10.31 | 16.26 | 25.89 | 33.12 | |||||||||||
| Operating & Other expenses | 5.96 | 4.04 | 8.52 | 9.45 | 13.14 | 15.83 | 8.46 | |||||||||||
EBITDA | 9.70 | 12.17 | 18.32 | 25.24 | 43.46 | 53.87 | 61.35 | 76.47 | — | |||||||||
| Depreciation/Amortization | 1.85 | 2.84 | 3.76 | 6.87 | 7.25 | 10.41 | 9.78 | 12.51 | — | |||||||||
| PBIT | 7.85 | 9.33 | 14.56 | 18.37 | 36.21 | 43.46 | 51.57 | 63.96 | — | |||||||||
| Interest & Other Items | 1.01 | 1.43 | 2.59 | 2.42 | 1.90 | 2.41 | 2.82 | 6.99 | — | |||||||||
| PBT | 6.84 | 7.90 | 11.97 | 15.95 | 34.31 | 41.05 | 48.75 | 56.97 | — | |||||||||
| Taxes & Other Items | 0.07 | -0.14 | 2.56 | 4.23 | 9.48 | 10.34 | 12.32 | 14.55 | — | |||||||||
| Net Income | 6.77 | 8.04 | 9.41 | 11.72 | 24.83 | 30.71 | 36.43 | 42.42 | — | |||||||||
| EPS | 7.45 | 8.85 | 9.81 | 11.61 | 24.60 | 30.42 | 36.09 | 42.02 | — | |||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
BETA Company Updates
BETA Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
BETA Past Performance & Peer Comparison
BETA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Beta Drugs Ltd | 42.36 | 11.44 | — |
| Sun Pharmaceutical Industries Ltd | 36.65 | 5.97 | 0.96% |
| Cipla Ltd | 23.13 | 3.90 | — |
| Dr Reddy's Laboratories Ltd | 19.74 | 3.95 | 0.60% |
BETA Stock Price Comparison
Compare BETA with any stock or ETFCompare BETA with any stock or ETF
BETA
BETA Holdings
BETA Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
BETA Promoter Holdings Trend
BETA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BETA Institutional Holdings Trend
BETA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BETA Shareholding Pattern
BETA Shareholding Pattern
BETA Shareholding History
BETA Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing BETA stock
smallcases containing BETA stock
Looks like this stock is not in any smallcase yet.
BETA Events
BETA Events
BETA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BETA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
BETA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BETA has not given any dividends in last 5 years
BETA Dividends
BETA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeBETA Stock News & Opinions
BETA Stock News & Opinions
Articles & Videos
Corporate
Beta Drugs to conduct board meeting
Beta Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Beta Drugs announces board meeting date
Beta Drugs will hold a meeting of the Board of Directors of the Company on 27 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Beta Drugs to conduct board meeting
Beta Drugs will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Beta Drugs to conduct board meeting
Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Beta Drugs schedules AGM
Beta Drugs announced that the 19th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Stock market update: Stocks that hit 52-week highs on NSE
1 year agoEconomic Times
Stock market update: Stocks that hit 52-week highs on NSE in today’s trade
3 years agoEconomic Times
Stock market update: Stocks that hit 52-week highs on NSE
3 years agoEconomic Times
Future Of Smart Beta ETF | NSE India ETF Conference
6 years agoCNBC-TV18
Trading Hour | Motilal Oswal AMC Says 2018 is a Year for Stock Pickers | CNBC TV18
6 years agoCNBC-TV18
Over the last 5 years, revenue has grown at a yearly rate of 34.98%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.02% to 0.08%
Over the last 5 years, net income has grown at a yearly rate of 35.28%, vs industry avg of 15.29%